<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>aaspjournal</PublisherName>
      <JournalTitle>Journal of Asian Association of Schools of Pharmacy</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 10</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>January - December, 2021</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>28</Day>
      </PubDate>
      <ArticleType>Pharmacy</ArticleType>
      <ArticleTitle>CYLD: a novel stratification marker for malignant tumors</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>17</FirstPage>
      <LastPage>22</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Shunsuke</FirstName>
          <LastName>Miyake</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Ayumi</FirstName>
          <LastName>Kanemaru</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Hideyuki</FirstName>
          <LastName>Saito</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Hirofumi</FirstName>
          <LastName>Jono</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>In recent years, many molecular-targeted drugs have been developed, and cancer treatment has advanced enormously. Because intratumoral heterogeneity represents genetic and molecular differences affecting patients’ response to these therapeutic drugs, establishing personalized therapy based on precise molecular pathogenesis is urgently required to maximize the therapeutic effects. Cylindromatosis (CYLD), a tumor suppressor gene, is closely associated with malignant transformation and poor prognosis in various malignant tumors. Increasing clinical evidence suggests that CYLD dysfunction by loss of its expression may play key roles in the molecular pathogenesis of various tumors. Moreover, we recently discovered that loss of CYLD expression not only be involved in malignant transformation, but also serves as a prognostic and predictive biomarker for molecular diagnosis and cancer treatment. In this review, we introduce the clinical significance of CYLD expression in various malignant tumors, and discuss the possibility of personalized therapy focusing on molecular diagnosis using CYLD expression.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>CYLD, malignant tumor, stratification marker</Keywords>
      <URLs>
        <Abstract>https://aaspjournal.org/ubijournal-v1copy/journals/abstract.php?article_id=13045&amp;title=CYLD: a novel stratification marker for malignant tumors</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>